EU Regulators Close Antitrust Probe into Edwards Lifesciences

The European Commission has officially ended its antitrust investigation into Edwards Lifesciences (EW.N), a leading manufacturer of cardiovascular medical devices. The inquiry, initiated in September 2023, focused on whether Edwards’ “Anti-Copycatting” policy restricted competitors and violated EU competition law.

Following unannounced inspections and regulatory review, Edwards Lifesciences voluntarily withdrew the policy from its website. This move prompted the Commission to close the case, signaling that the company is no longer under investigation.

The decision highlights the EU’s continued vigilance in safeguarding competition within the healthcare sector, ensuring that innovation remains accessible and that dominant players do not impose restrictive practices.

Key Highlights

• Investigation Origin: Launched in September 2023 after surprise inspections into Edwards’ market practices.
• Policy in Question: The “Global Unilateral Pro-Innovation (Anti-Copycatting) Policy” raised concerns of limiting rivals.
• Company Response: Edwards Lifesciences removed the policy from its website.
• Regulatory Outcome: The European Commission closed the probe, citing no further grounds for investigation.
• Sector Impact: Reinforces EU’s commitment to fair competition in medical technology markets.

Sources: European Commission Press Release, Mirage News